Citations

Showing 10 of 108094 citations.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
Fahn, Stanley, Espay, Alberto J. , Trenkwalder, Claudia , Adler, Charles H. , Patni, Rajiv, Johnson, Reed, Espay, Alberto J , Adler, C H , Isaacson, Stuart , Pahwa, Rajesh , Tanner, Caroline M.

Mayo Clinic

Movement Disorders Clinical Practice | February 5, 2018 | Volume: 5 | Issue: 2 | Pages: 183-190

10.1002/mdc3.12595 | PMID 29780852 Get It

AbstractBackgroundADS‐5102 (amantadine) extended release capsules (GOCOVRI™) are a treatment for dyskinesia in patients with Parkinson's disease (PD). ADS‐5102 reduced dyskinesia and OFF time in phase 3 controlled trials of up to six months. Amantadine immediate release (IR) is used for dyskinesia, but suboptimal durability and tolerability limit its clinical utility.MethodsIn an ongoing, open‐label, phase 3 study in the US and Western Europe (NCT02202551), patients with PD received 274 mg of ADS‐5102 (equivalent to 340 mg amantadine HCl) once daily at bedtime for up to two years. Study outcomes included safety and assessment of motor complications, as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) Part IV. This manuscript focuses on those patients switched to ADS‐5102 from amantadine IR. Results in two groups of patients who previously completed a randomized controlled trial (EASE LID or EASE LID 3) are also presented according to use of ADS‐5102 or placebo in that study before enrollment in the open‐label study.ResultsChange in MDS‐UPDRS Part IV at week 8 was –0.3 in the previous ADS‐5102 subgroup (n = 61), –3.4 in the previous placebo subgroup (n = 79), and –3.4 in the previous amantadine IR subgroup (n = 32). Effects were maintained to week 64. In the previous amantadine IR subgroup (mean treatment duration, 2.5 years), mean amantadine IR dose was 221 mg. Safety data were consistent with previous randomized controlled trials of ADS‐5102.ConclusionThese open‐label data suggest ADS‐5102 provides incremental reduction from baseline in MDS‐UDPRS Part IV score in patients switched directly from amantadine IR, without exacerbating adverse events.
Clinical presentation of autoimmune and viral encephalitides
Dubey, Divyanshu , Toledano, Michel , McKeon, Andrew , McKeon, Andrew , Dubey, Divyanshu

Mayo Clinic

Current Opinion in Critical Care | February 4, 2018 | Volume: 24 | Issue: 2 | Pages: 80-90

10.1097/mcc.0000000000000483 | PMID 29401173 Get It

Purpose of review We describe clinical and diagnostic features of various autoimmune and viral encephalitis subtypes. Recent findings Population-based studies have demonstrated both autoimmune and viral causes have similar prevalence and incident rates. Repertoire of autoimmune biomarkers has considerably increased with discovery of many novel neural antibodies including glial fibrillary acidic proteinα-immunoglobulin G. Similarly, with use of next generation sequencing and DNA libraries, many viral causes are being detected which would have been categorized as encephalitis of unknown cause a decade ago. Summary Autoimmune and viral encephalitides can resemble one another and sometimes autoimmune encephalitis may be triggered by viral infections. Early diagnosis and treatment is the key to both causes, which emphasizes the importance of clinical diagnosis before laboratory confirmation.
Modern diagnosis of GERD: the Lyon Consensus
Gyawali, C. Prakash , Savarino, Edoardo , Mion, François , Smout, A. J. P. M. , Vaezi, Michael F. , Fox, Mark , Vela, Marcelo F. , Tack, Jan , Bredenoord, Albert J. , Pandolfino, John E. , Roman, Sabine , Fox, Mark R , Roman, S , Gyawali, C P , Tack, Jan , Savarino, Edoardo , Kahrilas, Peter J. , Zerbib, Frank , Sifrim, Daniel , Tutuian, Radu I.

Mayo Clinic

Gut | February 3, 2018 | Volume: 67 | Issue: 7 | Pages: 1351-1362

10.1136/gutjnl-2017-314722 | PMID 29437910 Get It

Clinical history, questionnaire data and response to antisecretory therapy are insufficient to make a conclusive diagnosis of GERD in isolation, but are of value in determining need for further investigation. Conclusive evidence for reflux on oesophageal testing include advanced grade erosive oesophagitis (LA grades C and D), long-segment Barrett’s mucosa or peptic strictures on endoscopy or distal oesophageal acid exposure time (AET) >6% on ambulatory pH or pH-impedance monitoring. A normal endoscopy does not exclude GERD, but provides supportive evidence refuting GERD in conjunction with distal AET <4% and <40 reflux episodes on pH-impedance monitoring off proton pump inhibitors. Reflux-symptom association on ambulatory reflux monitoring provides supportive evidence for reflux triggered symptoms, and may predict a better treatment outcome when present. When endoscopy and pH or pH-impedance monitoring are inconclusive, adjunctive evidence from biopsy findings (histopathology scores, dilated intercellular spaces), motor evaluation (hypotensive lower oesophageal sphincter, hiatus hernia and oesophageal body hypomotility on high-resolution manometry) and novel impedance metrics (baseline impedance, postreflux swallow-induced peristaltic wave index) can add confidence for a GERD diagnosis; however, diagnosis cannot be based on these findings alone. An assessment of anatomy, motor function, reflux burden and symptomatic phenotype will therefore help direct management. Future GERD management strategies should focus on defining individual patient phenotypes based on the level of refluxate exposure, mechanism of reflux, efficacy of clearance, underlying anatomy of the oesophagogastric junction and psychometrics defining symptomatic presentations.
334 Post Priapism PROPPER Data Shows Good Satisfaction and Functional Outcomes
Wallen, J.J., Kansas, Bryan, Köhler, Tobias S. , Karpman, Edward , Christine, Brian, Khera, Mohit , Jones, LeRoy, Bennett, Nelson , Rhee, Eugene, Brant, William O. , Bella, Anthony J, Henry, Guillaume

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S90-S91

10.1016/j.jsxm.2017.11.214 Get It

327 Impact of Collagenase Clostridium Histolyticum on Erectile Function in Peyronie's Disease Patients
Ziegelmann, M., Trost, L., Bole, Raevti

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S87-S87

10.1016/j.jsxm.2017.11.207 Get It

316 Factors Associated with Chronic Pain Following Penile Prosthesis Implantation
Avant, R., Alom, M. , Ziegelmann, Matthew , Köhler, Tobias , Trost, Landon , Bole, Raevti

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S83-S83

10.1016/j.jsxm.2017.11.198 Get It

314 Regret with Penile Prosthesis: Characteristics and Factors of Dissatisfied Men
Alom, Mulham , Avant, R., Ziegelmann, Matthew , Köhler, Tobias , Trost, Landon , Bole, Raevti

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S82-S83

10.1016/j.jsxm.2017.11.197 Get It

219 Curvature Correction Techniques For Residual Curvature After Penile Prosthesis Placement: From Personal Opinion To Objective Data
Jani, K. , Bella, Anthony J, Bennett, Nelson , Brant, W., Christine, Brian, Jones, LeRoy, Kansas, Bryan, Khera, M, Köhler, Tobias , Rhee, Eugene, Karpman, Edward , Henry, Guillaume

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S74-S74

10.1016/j.jsxm.2017.11.179 Get It

207 Single Center Experience Using Doppler Assessment for Erectile Dysfunction (ED) Complaint in More Than 500 Patients
Schommer, Eric, Pathak, Ram A. , McNulty, Zachary, Shah, Raj , Broderick, Gregory A.

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S67-S68

10.1016/j.jsxm.2017.11.166 Get It

193 Comparison of Lower Urinary Tract Symptoms and Sexual Function Response to Convective Radiofrequency Thermal Therapy of Prostate (Rezűm®) to MTOPS Study Cohort
Gupta, Natasha , Holland, Bradley , Dynda, Danuta, Köhler, Tobias , McVary, K.T., Helo, Sevann , Tadros, Nicholas N.

Mayo Clinic

The Journal of Sexual Medicine | February 3, 2018 | Volume: 15 | Issue: Supplement_1 | Pages: S61-S61

10.1016/j.jsxm.2017.11.152 Get It